Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ramucirumab plus best supportive care in second-line hepatocellular carcinoma with elevated AFP after sorafenib
MOH_2017-03-20_000210Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Ramucirumab + best supportive care with Placebo + best supportive care (2 arms). Started Jul 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on MOH_2017-03-20_000210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-20_000210.